ArticleCellular oncology (Dordrecht, Netherlands)2026
Upregulated ARMCX1 suppresses nasopharyngeal carcinoma progression by promoting TRIM21-mediated β-catenin degradation.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated Multi-Omics Analysis Constructs an Intratumoral Heterogeneity-Corrected Prognostic Signature for Cervical Cancer.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArmadillo repeat-containing X-linked 1 (ARMCX1) has been reported to exhibit a suppressive effect in a variety of solid tumors. However, neither its biological role nor its potential mechanism of action has yet been reported in nasopharyngeal carcinoma (NPC).
methodsImmunohistochemical staining of an NPC tissue microarray was performed to evaluate the clinicopathologic association between ARMCX1 and NPC patients. The effect of ARMCX1 on the growth, migratory, and invasive capacities of NPC cells was assessed in vitro using colony formation, Cell Counting Kit-8 (CCK-8), 5-ethynyl-2’-deoxyuridine (EdU), scratch, and Transwell assays. A subcutaneous graft tumor model was implemented to investigate the impact of ARMCX1 on the tumor growth of NPC cells in vivo. Western blotting, immunofluorescence staining, and cycloheximide and proteasome inhibitor experiments were employed to investigate the potential molecular mechanisms of ARMCX1 in NPC
resultsOverexpression of ARMCX1 effectively inhibited the growth, migration, and invasion in NPC cells. Western blotting, co-immunoprecipitation, immunofluorescence, and cycloheximide and proteasome inhibitor experiments revealed that ARMCX1 mediated the β-catenin ubiquitination and degradation via recruiting tripartite motif-containing protein 21 (TRIM21), thereby suppressing cell cycle progression and epithelial–mesenchymal transition. Final rescue assays demonstrated that β-catenin reversed ARMCX1-mediated suppression of NPC cell proliferation, migration, and invasion.
conclusionsARMCX1 attenuates NPC cell proliferation, migration, and invasion by binding β-catenin and promoting its ubiquitination-dependent degradation via TRIM21. Hence, ARMCX1 may serve as a potential molecular target for therapeutic intervention in NPC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.